Why Novartis's CEO Just Took a Seat at AI's Most Interesting Table

Daniela Amodei, Anthropic's co-founder and president, said: "Getting powerful new technology to people safely and at scale is what we think about every day at Anthropic. Vas has been doing exactly that for years." Neil "Buddy" Shah, who chairs the Long-Term Benefit Trust, pointed to his "career in stewarding breakthrough science." Translation: they didn't recruit a pharma guy to check a box. They recruited him because regulating powerful, potentially dangerous technology is literally his day job.

Pharma's AI Obsession Is Getting Serious

Narasimhan's board seat isn't happening in a vacuum. It's the most visible peak of a trend that's been building for years.

Consider the landscape. Eli Lilly appointed Thomas Fuchs, the former dean of AI at Mount Sinai, as its Chief AI Officer and inked a partnership with NVIDIA reportedly worth $1 billion over five years. Pfizer created a Chief AI and Analytics Officer role. Merck did the same. A recent analysis identified over 100 "AI-friendly" CEOs and board members across pharma and tech, with 55% focused specifically on drug development.

The money matches the enthusiasm. Bloomberg surveyed 50 C-suite pharma leaders and found that 91% believe AI will be transformative for their industry. Three-quarters are already actively using or testing it. McKinsey estimates AI could unlock $110 billion in annual value across 21 different pharma use cases.

Think of it like the early days of the internet in finance. Everyone knew it mattered. The question was who would figure it out first.

Inside Novartis's AI Playbook

Narasimhan hasn't just been talking about AI at Novartis; he's been spending on it.

The company has a long-running strategic alliance with Microsoft focused on generative chemistry and AI-driven drug discovery. It partnered with Generate:Biomedicines in a deal worth up to $1 billion to use generative AI for designing entirely new protein drugs. And it built a next-generation clinical platform on AWS that uses AI for everything from trial protocol design to document generation.

In February 2026, Novartis broke ground on a 466,000-square-foot Biomedical Research Center in San Diego with AI, data, and computational capabilities baked into the architecture from day one. The facility will house about 1,000 employees working on neuroscience, oncology, and gene therapies. It's part of a broader $23 billion investment in U.S. R&D and manufacturing.

This isn't a side project. It's the whole strategy.

What This Really Means

Let's zoom out for a second. Why does a board seat matter?

Because boards shape direction. Narasimhan now has a voice in how one of the world's most advanced AI companies thinks about healthcare, safety, and regulation. And Anthropic gets something equally valuable: a guide who's navigated the FDA, global drug approvals, and the messy reality of deploying cutting-edge science in actual human beings.

Narasimhan himself framed it around the science. He pointed to AI's potential for understanding disease biology and designing better medicines, drawing from his early career fighting infectious diseases in low-income countries.

But there's a bigger strategic play here. Anthropic just raised its Series G at a staggering $380 billion post-money valuation and appears to be gearing up for an IPO. Adding a pharma heavyweight to the board sends a clear message: healthcare isn't a "nice to have" vertical for Anthropic. It's a core growth market.

For Novartis, the calculus is just as clear. Having your CEO embedded in the governance of a frontier AI company gives you a front-row seat to the technology that could reshape how drugs are discovered, tested, and approved. It's like having a scout permanently stationed at the draft combine.

The Bigger Picture

We're watching two of the most powerful industries on the planet merge in real time. Pharma brings regulatory expertise, biological data, and the world's hardest unsolved problems. AI brings speed, pattern recognition, and the ability to search billions of molecules before breakfast.

The executives who sit at the intersection of both worlds will define the next decade of medicine. With this appointment, Narasimhan just planted his flag at that intersection.

The question isn't whether AI will transform drug development. It's whether the people steering these AI companies understand what's at stake when the patient isn't hypothetical. Anthropic just bet that having a doctor on the board is a good place to start.

The Gene Therapy Company Betting Against Million-Dollar Price Tags

Gene therapies can cost millions per patient, and most never achieve commercial success. Ocugen's CEO thinks the industry is solving the wrong problem, and he's betting the company on manufacturing scale and affordable pricing over scientific novelty.